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Abstract
The availability of a robust disease model is essential for the development of countermeasures for Middle East respiratory
syndrome coronavirus (MERS-CoV). While a rhesus macaque model of MERS-CoV has been established, the lack of uniform,
severe disease in this model complicates the analysis of countermeasure studies. Modeling of the interaction between the
MERS-CoV spike glycoprotein and its receptor dipeptidyl peptidase 4 predicted comparable interaction energies in common
marmosets and humans. The suitability of the marmoset as a MERS-CoV model was tested by inoculation via combined
intratracheal, intranasal, oral and ocular routes. Most of the marmosets developed a progressive severe pneumonia leading
to euthanasia of some animals. Extensive lesions were evident in the lungs of all animals necropsied at different time points
post inoculation. Some animals were also viremic; high viral loads were detected in the lungs of all infected animals, and
total RNAseq demonstrated the induction of immune and inflammatory pathways. This is the first description of a severe,
partially lethal, disease model of MERS-CoV, and as such will have a major impact on the ability to assess the efficacy of
vaccines and treatment strategies as well as allowing more detailed pathogenesis studies.
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Introduction
Since the emergence of MERS-CoV in 2012, researchers have
worked to establish animal disease models to study the pathogen-
esis of this virus and to develop effective countermeasures. With
over 836 cases and at least 290 deaths [1], there has been a rapid
increase in the number of MERS-CoV cases as diagnostics are
being more widely applied. While dromedary camels are suspected
to be involved in zoonotic transmission of MERS-CoV [2–5]; and
camel as well as horse DPP4 can efficiently facilitate virus entry
[6], the mechanism(s) by which most people acquire MERS-CoV
is still unclear. Since targeted attempts to prevent zoonotic
transmission are currently not feasible and significant morbidity
and mortality still occur in individuals with comorbidities,
developing effective prophylactic and therapeutic treatment
strategies remains a high priority. Although several treatment
regimens have been suggested for use in patients based on in vitro
MERS-CoV studies or treatment implemented during the SARS-
CoV pandemic, only one such treatment has been tested in vivo
against MERS-CoV to date [7]. To enable a better evaluation of
MERS-CoV treatment and prevention strategies, an animal model
more representative of severe human disease is crucial.
Assessment of potential treatments in relevant animal disease
models is essential prior to conducting clinical trials. Attempts to
generate small animal models of disease have so far not been
successful. Mice [8,9], hamsters [10] and ferrets [11] do not
support replication of MERS-CoV in what appears to be a
receptor dependent manner. To overcome this impediment, it was
recently demonstrated that adenovirus vectored transduction of
human DPP4 into multiple strains of mice, including various
knock-outs, results in productive infection and mild pneumonia
[12]. Notwithstanding the aforementioned mouse models, the only
PLOS Pathogens | www.plospathogens.org 1 August 2014 | Volume 10 | Issue 8 | e1004250
naturally permissive MERS-CoV disease model that has been
described to date is the rhesus macaque model [13–15]. In the
rhesus macaque, MERS-CoV causes a transient infection of the
lower respiratory tract resulting in mild to moderate clinical
disease. While this model is useful, it seems to recapitulate the mild
disease observed in some human cases, rather than the more
severe or even lethal disease observed in many human cases.
Moreover, although this model has been used to assess treatment
strategies [7,16], it can be difficult as an evaluative model for
therapeutics as clinical signs are mild, the duration of illness is
relatively short and virus replication is limited.
Dipeptidyl peptidase 4 (DPP4, also known as CD26) was
recently shown to be the cellular receptor for MERS-CoV [17],
and the interaction between the MERS-CoV spike protein and
DPP4 was subsequently determined by co-crystallography studies
[18,19]. Although DPP4 is a relatively conserved protein in
general, recent data have shown that receptor specificity is likely a
major factor in the species tropism of MERS-CoV [11,20]. This
suggests that mapping the spike binding region of DPP4 of a
species of interest before performing experimental inoculations of
animals could provide a more rational approach to identifying
MERS-CoV susceptible animal models. Here, we modeled the
interaction of the common marmoset DPP4 with the MERS-CoV
spike protein and show that no differences exist compared to
human DPP4 at the site of interaction. Subsequent inoculation of
common marmosets (Callithrix jacchus) resulted in severe, even
lethal, respiratory disease in inoculated animals, with widespread,
coalescing bronchointerstitial pneumonia and high viral loads in
the lungs of all animals.
Results
Common marmoset DPP4 is predicted to bind the MERS-
CoV spike glycoprotein
Variations in the DPP4 receptor appear to play a major role in
the ability of MERS-CoV to infect certain animal species. To
predict the ability of MERS-CoV spike protein to bind to
marmoset DPP4, analyses were performed using human DPP4
(known to bind MERS-CoV spike glycoprotein) [17] and ferret
DPP4 (unable to bind MERS-CoV spike glycoprotein) [11].
Comparison of the amino acid alignments of human, ferret and
marmoset DPP4 revealed that marmoset DPP4 is 96.4% identical
to human DPP4, while ferret DPP4 is 87.4% identical to human
and 87.5% identical to marmoset DPP4. Recently, the 14 amino
acids in human DPP4 that facilitate binding to the receptor-
binding domain (RBD) of the MERS-CoV spike glycoprotein were
identified by co-crystallography studies [18,19]. No amino acid
differences between human, rhesus macaque and common
marmoset were identified within the DPP4 region interacting
with the MERS-CoV RBD, whereas between human/rhesus/
marmoset and ferret and mouse nine or six amino acid residues
were different within this region, respectively (Fig. 1A). The 100%
identity of the 14 amino acid residues between human and
marmoset DPP4 in the interaction regions indicates that MERS-
CoV RBD should bind to marmoset DPP4. This was further
supported by modeling the binding potential between human,
ferret and marmoset DPP4 with the MERS-CoV RBD. No
significant differences in binding energy were observed between
the human (2981) and marmoset (2978) DPP4 – MERS-CoV
RBD, whereas the binding energies between ferret DPP4 and the
MERS-CoV RBD was significantly higher (2601). A marmoset
DPP4 homology model was built using the human DPP4 structure
(PDB ID: 4KR0, Chain A). This model demonstrated that all
amino acid differences between human and marmoset DPP4 were
located away from the binding region of DPP4 with the S1 portion
of the spike glycoprotein; the nearest residues to this interface that
differ are Arg343, Ile193 and Val279 which are 14A, 10A and
13A away, respectively, from the nearest atom in MERS-S
(Fig. 1B). Taken together this suggests that marmoset DPP4 would
facilitate binding with the MERS-CoV RBD and that marmosets
would be susceptible to MERS-CoV infection.
Common marmosets develop severe respiratory disease
following inoculation with MERS-CoV
Common marmosets inoculated with MERS-CoV (hCoV-
EMC/2012 [21]) via the intratracheal, intranasal, oral and ocular
routes developed signs of respiratory disease that ranged from
moderate to severe (Table S1). Animals were assigned for
scheduled necropsies on 3 (CM1, CM2 and CM3) and 6 (CM4,
CM5 and CM6) dpi prior to the start of the experiment; three
additional animals (CM7, CM8 and CM9) were monitored for
survival (Fig. 2A). Starting on 1 dpi six of nine animals showed
increased respiration rates while all animals had increased
respiration rates from 2 dpi on. In some of the animals open
mouth and/or labored breathing was evident from 3 dpi onwards.
All animals showed loss of appetite and decreased levels of activity.
Clinical scores were assigned using an established scoring sheet for
respiratory disease in common marmosets (Table S2). Based on
this system, peak clinical scores were observed between 4 and
6 dpi with scores returning to baseline by 13 dpi in the two
remaining animals (Fig. 2B). Animals exhibited decreased tem-
peratures starting on 3 dpi, returning to a normal range on 9 dpi
(Fig. S1A). On 4 dpi, two animals (CM5 and CM9) were
euthanized due to the severity of disease as determined by clinical
score (Fig. 2A), which included increased respiration rate, open
mouth breathing and failure to move following prompting. One of
these animals also exhibited the presence of frothy hemorrhagic
discharge from its mouth. While most animals showed a decrease
in body temperature by 3 dpi; the two animals that were
euthanized on 4 dpi were severely hypothermic indicative of the
onset of shock at the terminal stages of disease (Fig. S1A).
Clinically significant alterations in blood cell counts and chemistry
were not noted in any of the animals (Fig. S1B–J) in contrast to the
rhesus macaque model. As serial blood samples could not be
Author Summary
The development of vaccines and treatment strategies is
aided by robust animal disease models that accurately
depict the illness that is observed in humans. Here we
describe a new, improved model for MERS-CoV using the
common marmoset, whereby the severe, and even lethal,
illness that has been observed in many human cases is
recapitulated. Prior to the development of this model, the
only available animal models for MERS-CoV infection were
the rhesus macaque and a mouse model that requires
adenovirus-transduced expression of the human version of
the protein required for virus entry. The rhesus macaque
model more closely mimics the mild to moderate disease
observed in some patients—mainly those without signif-
icant comorbidities. The increased severity of illness in the
common marmoset model is an important advance in the
ability to evaluate potential therapeutic agents against
MERS-CoV, as discrimination between successfully treated
and control animals should be more apparent. In addition,
the closer models recapitulate the disease observed in
humans, the more likely findings can be eventually
translated into use in humans.
Common Marmosets Are a Severe Disease Model of MERS-CoV Infection
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collected on a daily basis on marmosets, due to the small size of the
animals, alterations were likely missed as a result of study design.
Elevations in liver enzymes (Fig. S1E–G) and measures of kidney
function (Fig. S1I,J) occurred on 3 and 4 dpi, respectively;
however, these changes were not outside of the normal range.
The animals euthanized on 3, 4 and 6 dpi all showed hypopro-
teinemia consistent with high protein pulmonary effusions
resulting from alveolar edema (Fig. S1K,L).
Respiratory disease is characterized by progressive
severe pneumonia with extensive lung pathology
To monitor for signs of pneumonia animals underwent dorsal-
ventral and lateral x-rays during examinations on 0, 1, 3, 6, 9, 13
and 20 dpi. All radiographs were normal prior to inoculation on
0 dpi, while on 1 dpi four of nine animals showed mild to marked
diffuse interstitial infiltration in the lower lung lobes (Table S3).
On 3 dpi interstitial infiltration of varying severity (mild to severe)
was noted in all animals bilaterally in the lower lobes. The two
animals that were euthanized on 4 dpi showed severe interstitial
infiltration with partial to complete congestion of the bronchioles
(Fig. 3). The other animals were not radiographed at this time
point as this was not a scheduled examination time point. On
6 dpi the remaining animals had mild to severe interstitial
infiltration in the lower lobes. One animal (CM6) had severe
infiltration in all lobes with congested bronchioles. By 9 dpi the
two remaining animals showed improvement, with lessening
infiltration, which was resolved by 13 dpi.
Three animals were euthanized on 3 dpi and necropsies were
performed. All three animals had relatively comparable gross
lesions (Fig. S2A), especially in the lower lobes (mean affected area
11% of upper lung lobes, 54% of lower lung lobes), with multifocal
consolidation and dark red discoloration, consistent with intersti-
tial pneumonia. The two animals euthanized due to the severity of
disease on 4 dpi showed extensive severe lesions throughout the
lungs (mean affected area 36% of upper lung lobes, 83% of lower
Figure 1. Interaction between the MERS-CoV spike glycoprotein (S1) and its receptor dipeptidyl peptidase 4 (DPP4). (A) Alignment of
the amino acid residues from human, common marmoset and ferret DPP4 that have been identified to interact with the receptor binding domain of
the MERS-CoV spike glycoprotein. (B) Interaction model (front, back and side view) of the MERS-CoV S1 and its cognate receptor human DPP4, with
amino acid differences in common marmoset DPP4 are highlighted in red.
doi:10.1371/journal.ppat.1004250.g001
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lung lobes) (Fig. 3, Fig. S2A). In addition, the lungs were firm,
failed to collapse and were fluid filled. The lungs from animal
CM5 were three times the lung weight to body weight ratio of the
lungs from the other sampled animals, which were comparable to
CM9 (Fig. S2B). Animals necropsied on 6 dpi revealed lungs
comparable to 4 dpi with lesions throughout the lungs (mean
affected area 12% of upper lung lobes, 85% of lower lung lobes)
(Fig. S2A). Lungs from these animals were firm and fluid filled,
with fluid leaking from the tissue and had a lung to body weight
ratio twice that of 3 dpi animals (Fig. S2B). No other gross
pathological changes were observed at necropsy.
Lungs develop extensive bronchointerstitial pneumonia
Lungs from marmosets necropsied at 3 and 4 dpi all showed
multifocal to coalescing, moderate to marked acute bronchointer-
stitial pneumonia (Fig. 4A,C). The pneumonia tended to be
centered on small caliber and terminal bronchioles and extended
into the adjacent pulmonary parenchyma. Viral antigen was
exclusively associated and located throughout regions that
contained pathological changes (Fig. 4B,D,F,H,J). The bronchio-
lar epithelium was frequently eroded, leaving attenuated bronchi-
olar epithelial cells. Affected bronchioles were filled with small to
moderate numbers of macrophages and neutrophils, and occa-
sionally small amounts of fibrin and edema (Fig. 4E,G). The
adjacent alveolar interstitium was thickened with congestion,
edema and fibrin and moderate numbers of macrophages and
neutrophils (Fig. 4E, Table S4). Alveolar spaces contained
moderate to marked numbers of pulmonary macrophages and
neutrophils; multifocally there was pulmonary edema, fibrin, and
less frequently hemorrhage (Fig. 4E). There were also rare
multinucleate syncytia within alveolar spaces (Fig. 4E). At 6 dpi
multifocal to coalescing areas of acute pneumonia were still visible;
however, there were also extensive areas of type II pneumocyte
hyperplasia (Fig. 4G) and consolidation of pulmonary fibrin
resulting in multifocal hyaline membranes (Fig. 4I). These changes
are consistent with a transition from acute to a more chronic
reparative stage of pneumonia. Regions that were undergoing
tissue remodeling showed evidence of clearing of viral antigen
(Fig. 4 H). The distribution of DPP4 in marmoset lungs included
type I pneumocytes (Fig. 5A) as well as bronchiolar epithelial cells
and smooth muscle cells. Consistent with this location of DPP4, a
two-color fluorescent staining for cytokeratin and viral antigen, as
well as in situ hybridization to detect viral RNA, identified type I
pneumocytes and alveolar macrophages as the primary cell type
for MERS- CoV replication (Fig. 5 B,C). One of the surviving
animals (CM7) had to be euthanized prior to the scheduled end of
the study (48 dpi) and was found to have severe aspiration
pneumonia. The lungs from the other surviving animal (CM8)
appeared normal at necropsy 55 dpi. Viral antigen was not
detected by IHC in either animal indicating that these animals had
resolved MERS-CoV infection. All other lesions noted in the
remaining tissues, such as interstitial nephritis in the kidney and
the presence of giant cells in the adrenal gland, consistent with
extramedullary hematopoiesis, were not considered to be clinically
significant since they are typical, incidental findings in common
marmosets [22].
Viral RNA is present in swabs and blood
On 1, 3, 6, 9, 13 and 20 dpi, nasal and oropharyngeal swabs
were obtained from all remaining animals; on 4 dpi before
euthanasia, swabs were also obtained from CM5 and CM9. All
but one of the nasal swabs collected on 1 dpi were positive for the
presence of viral RNA by qRT-PCR (Fig. 6A). By 3 dpi, viral
loads in nasal and oropharyngeal swabs were lower than on 1 dpi.
However, swabs collected from CM5 and CM9 at the time of
euthanasia at 4 dpi contained the highest viral loads. In the
surviving animals, viral loads in the swabs decreased over time and
all swabs were negative by 20 dpi (Fig. 6A). A terminal blood
sample was collected from animals CM1–CM6 and CM9. CM5,
euthanized on 4 dpi, and CM4, euthanized on 6 dpi, were viremic
(Fig. 6B), although viral loads in these blood samples were very
low and virus isolation attempts on blood samples were not
successful (data not shown).
Marmosets develop disseminated viral infection
Upon necropsy of the animals on 3, 4 and 6 dpi, tissue samples
were collected and subsequently analyzed for the presence of viral
RNA by qRT-PCR. High viral loads were detected mainly in
respiratory tissues (Fig. 6C). Viral loads in lung tissue samples
obtained from the animals on 3 dpi were very high, reaching up to
107 TCID50 eq./gram. Viral loads in the lungs did not decrease
between 3 and 6 dpi. Viral RNA was detected in all tested tissues,
albeit not in every animal (Fig. 6D). Viral RNA was not detected
in the lungs, or other tissues, from the two surviving animals that
were euthanized on 48 and 55 dpi; however, both of these animals
seroconverted indicating that they had been exposed to MERS-
CoV. Virus isolation attempts were performed on nasal mucosa,
trachea, lung and kidney samples. In all animals except CM6
(6 dpi), virus could be isolated from one or more lung lobes (Table
S5). Virus was isolated from all trachea samples collected on 4 and
Figure 2. Experimental schedule and clinical parameters. (A)
Scheduled necropsies are indicated above and actual necropsies below
the timeline. CM1–CM9 indicate the study animals. (B) Animals were
scored daily and their mean clinical score 6SD calculated. The number
of animals remaining in the experiment is indicated above the bar on
each day.
doi:10.1371/journal.ppat.1004250.g002
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6 dpi. Virus was not isolated from any of the kidney samples
(Table 5).
Transcriptional changes support increased inflammatory
processes
To characterize transcriptional changes as a result of MERS-
CoV infection, we performed whole transcriptional sequencing on
RNA samples extracted from the right lower lobe of marmoset
lungs collected at necropsy. Samples were collected from areas of
the lung that contained gross lesions. These were compared to the
total RNAseq data from the lung of a single uninfected marmoset
obtained through the Non-Human Primate Reference Transcrip-
tome Resource (http://www.nhprtr.org) [23]. We reasoned that
molecules induced by infection that play a role in respiratory
pathogenesis would at least double in abundance over the course
of infection. Therefore we identified mean differentially expressed
(DE) transcripts at each time point with at least 2-fold change
compared to the uninfected control.
Molecular profiles were functionally similar over the course of
sampling (Fig. 7A); however, there were some alterations in
functional category enrichment and magnitude of expression
relative to the uninfected control. Throughout infection, pathways
associated with chemotaxis and cell migration, cell cycle progres-
sion, cell proliferation, and fibrogenesis were increasingly activated
relative to the uninfected control lung, with higher expression and
greater pathway enrichment occurring at 4 and 6 dpi than at
3 dpi. We also observed activation of pathways associated with
inflammation, vascularization, endothelial activation, proliferation
of smooth muscle cells, and tissue repair, indicating that MERS-
CoV infection induces tissue differentiation in marmosets consis-
tent with development of pulmonary fibrosis (Fig. 7B, Table S6).
Despite the observed severe lung pathology, robust antiviral
transcriptional responses were induced in the marmoset lungs. Up
regulation of innate immune genes such as pattern recognition
receptors, interferon-stimulated genes, inflammatory cytokines and
signaling molecules, as well as adaptive immune responses such as
lymphocyte signaling, proliferation, and differentiation, immuno-
globulin production, antigen presentation, and T cell costimula-
tion were observed. We were able to detect many common serum
cytokine transcripts using RNAseq, which unfortunately cannot be
measured in immunoassays as these are not available for common
marmosets. Notably, we detected down regulation of interferon
gamma (IFNc) and its receptor (IFNGR1) at multiple time points,
and no expression of interferon beta (IFNb), consistent with
reports that MERS-CoV infection attenuates these cytokines [24–
29]. We did observe up regulation of the type I interferon receptor
(IFNAR1, IFNAR2) and interferon stimulated genes (ISGs)
induced by type I interferon responses, in addition to the type
III interferon receptor (IFNLR1), (Table S7). We also observed
significant down regulation of IL-8 and IL-18 at all time points,
and up regulation of IL-27 for all animals. IL-1b was up regulated
in the 4 dpi samples, but down regulated at 3 and 6 dpi. As
cytokine transcripts generally have a short half-life, in some cases
we were not able to detect DE cytokine transcripts, but were able
to detect changes in their receptors or molecules associated with
Figure 3. Radiographic alterations and lung pathology. Dorsal-
ventral and lateral thoracic x-rays from of common marmosets (CM)
imaged prior to MERS-CoV inoculation (day 0) and on days 3 and 4 post-
inoculation. Areas of interstitial infiltration, indicative of pneumonia, are
highlighted (circle). Positional indicators are included (R – right, L – left).
Gross pathology of the lungs from CM5 and CM9 necropsied on 4 dpi
are shown below indicating extensive gross lesions.
doi:10.1371/journal.ppat.1004250.g003
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cytokine signaling. We observed up regulation of the receptors for
IL-2 (IL2RB), IL-4 (IL4R), IL-6 (IL-6R), IL-17 (IL17RC,
IL17RE), IL-22 (IL22RA1), and IL-27 (IL27RA), and down
regulation of receptors for IL-1 (IL1R1, IL1RAP), IL-12
(IL12RB2), IL-18 (IL18R1), and IL-20 (IL20RA) (Table S7).
Using the Molecule Activity Prediction (MAP) tool in IPA, we
were able to generate a network of these molecules showing the
predicted activity of cytokines not identified in the dataset at 4 dpi
(Fig. 7C). The MAP tool utilizes relationships with molecules
neighboring the DE transcripts in this dataset to predict
transcriptional behavior. These relationships are based on
published work curated in the IPA knowledgebase, and provide
insight into the dynamics of all molecules within a given network
or pathway generated using the primary transcriptional data from
this experiment. While type I interferons, IL-2, IL-4, and IL-6
were predicted to be induced, type II interferons and the pro-
inflammatory cytokines IL-1 and TNFa were predicted to be at
least partially inhibited. While transcriptional induction of
proinflammatory cytokines such as IL-1 and TNFa was expected,
especially given the extent of inflammation in the lungs, the time
points for sampling may have been too late to catch TNFa
induction as it is one of the first cytokines induced during
inflammation. Its induction is supported by downstream effectors
such as NFkB, RelA, and RelB and many accessory proteins that
were unregulated at the time points investigated. Moreover, as
TNFa signaling tends to be down regulated rapidly, the up
regulation of SOCS3, which is induced by TNFa as part of a
negative feedback loop that ultimately results in suppression of
TNFa and IL-1, was observed at all time points.
Discussion
In MERS-CoV-infected common marmosets, clinical disease
was more severe than in the rhesus macaque, was of longer
duration and resulted in euthanasia of some animals. Viral loads in
the lungs were up to 1000 times higher than those in the rhesus
macaque lungs (mean viral load in the lungs 1.26103 in rhesus vs.
1.56106 in marmosets on 3 dpi; 6.86102 in rhesus vs. 2.16106 in
marmosets on 6 dpi) [15]. Two of the six animals that were not
euthanized at the scheduled 3 dpi necropsy had to be euthanized
due to severity of disease, making this the first lethal MERS-CoV
animal model. In both the marmoset and rhesus macaque [15]
models, viral replication occurred predominantly in the lower
respiratory tract; however, in marmosets MERS-CoV RNA was
also detected in the blood. This is suggestive of a more systemic
dissemination that was corroborated by the detection of viral RNA
in nearly all tested tissues in all infected animals. Taken together,
the data from the common marmoset model suggest that this
model more closely recapitulates severe, even lethal, human
disease caused by MERS-CoV. This differs from the rhesus
macaque model for MERS-CoV [13–15], which more closely
resembles mild to moderate human disease.
While viral RNA was detected in kidney samples from five out
of seven marmosets, no histological abnormalities were observed,
virus could not be isolated and viral antigen was not detected by
immunohistochemistry. Elevations in creatinine and blood urea
nitrogen levels were noted on 4 dpi in the two animals that were
euthanized, suggesting some degree of kidney involvement during
infection; however, the lack of evidence of virus replication in this
tissue suggests that this is not a direct viral effect. The acute renal
failure in some patients [21] may be a secondary effect of ARDS
[30] or other comorbidities and not primarily the result of direct
MERS-CoV damage to the kidneys. While evidence of pulmonary
fibrosis was not yet observed histologically at the time points
investigated, transcriptional evidence of the onset of fibrosis was
extensive. Previous studies of severe acute respiratory syndrome
coronavirus (SARS-CoV) have demonstrated that pulmonary
Figure 4. Histopathological changes in lungs of common marmosets inoculated with MERS-CoV. Common marmosets were euthanized
on day 3, 4 or 6 post inoculation and lung tissue was collected and stained with hematoxylin and eosin (H&E; panels A, C, E, G, I) or
immunohistochemistry using a polyclonal a-MERS-CoV antibody (IHC; panels B, D, F, H, J). (A) Acute bronchointerstitial pneumonia centered on
terminal bronchioles, with influx of inflammatory cells and thickening of alveolar septa in lung tissue collected on 3 dpi. Asterisk indicates essentially
normal tissue. (B) IHC staining of sequential section of panel A reveals abundance of MERS-CoV antigen in affected areas. (C) Coalescing
bronchointerstitial pneumonia inducing a diffuse lesion on 3 dpi. (D) IHC staining of sequential section of panel C reveals abundance of MERS-CoV
antigen in affected areas. (E) Edema, hemorrhage and fibrin (asterisks) fill the alveolar spaces in lung tissue collected on 3 dpi. Arrowhead indicates
syncytium. Inset highlights thickened alveolar interstitium with fibrin, edema and inflammatory cells. (F) IHC staining of sequential section of panel E.
(G) Type II pneumocyte hyperplasia is visible on 6 dpi, as highlighted further in inset. (H) IHC staining of sequential section of panel G indicates viral
antigen has been mostly cleared from remodeling tissue. (I) On 6 dpi, fibrin is consolidating into hyaline membranes (arrows). (J) IHC staining of
sequential section of panel I. Magnification: A, B, C and D 46; E, F, G, H, I and J 406; inset in panel E and G 1006.
doi:10.1371/journal.ppat.1004250.g004
Figure 5. The cellular tropism of MERS-CoV. (A) DPP4 is evident on type I pneumocytes (arrow), bronchiolar epithelial cells and
smooth muscle cells. (B) In situ hybridization demonstrating the presence of viral RNA in type I pneumocytes (black arrow) and alveolar
macrophages (blue arrow). (C) Type I pneumocytes (green) are lost following infection with MERS-CoV (lower right). Viral antigen (red) can be
observed in type I pneumocytes (arrow). Magnification: A 5006; B 2006; C 5006.
doi:10.1371/journal.ppat.1004250.g005
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fibrosis was a major mechanism of disease progression, and that
lung inflammation caused by infection induced fibrogenic
transcriptional programs [31–33]. In the marmosets, the role of
fibrosis is unknown and needs to be further clarified and supported
by data from human cases. We anticipate that studies using larger
groups of marmosets, additional control animals, and samples
collected at later time points post-infection will confirm the
histologic course of fibrosis progression, as well as the transcrip-
tional events underlying these pathogenic processes.
Currently, the only small animal MERS-CoV challenge model
available, requires transduction of animals with an adenovirus
vector expressing human DPP4 [12]. Although this is a very useful
model, MERS-CoV infection in this model is highly dependent on
the transduction of cells and level of DPP4 expression from the
adenovirus vector and thus does not necessarily reflect the natural
disease process. Therefore, therapeutics indicated to inhibit
MERS-CoV in in vitro studies likely need to be tested in one of
the two described nonhuman primate models. As such, marmosets
should likely serve as the animal of choice for future therapeutic
studies where possible. Not only does the more severe, and
potentially lethal disease set a higher bar for protection, it would
also allow a greater differentiation to be made between disease in
untreated animals versus treated animals, currently a limitation of
the rhesus macaque model [7]. The marmoset model also allows
the evaluation of intervention strategies at later time points as the
disease process in the rhesus model is rapid and quite transient.
However, late treatment that targets the virus, as with many
countermeasures, is unlikely to be successful once significant lung
damage has already occurred as was observed by the lack of
success of very late treatment with ribavirin and interferon in
human MERS-CoV cases [34]. To enable treatment of patients
prior to severe lung injury, future transcriptional studies may yield
early indicators of disease progression that can be used as
diagnostic or prognostic tests to improve clinical management.
The development of the more severe marmoset model will ensure
a better pre-clinical analysis of treatments prior to proceeding to
Figure 6. Viral load from marmosets inoculated with MERS-CoV in nasal and throat swabs (A), blood (B) and tissues (C,D). Nasal and
throat swabs were collected at exams while blood samples were only collected at necropsy. RNA was extracted and viral load was determined as
TCID50 equivalents by qRT-PCR. The number of animals included in the analysis at each time point in (A) is indicated above the graph. Respiratory (C)
and other tissues (D) were collected at necropsy on the indicated days post-inoculation. RNA was extracted and viral load determined as TCID50
equivalents per gram of tissue by qRT-PCR.
doi:10.1371/journal.ppat.1004250.g006
Figure 7. Transcriptional signatures of MERS-CoV infection in marmoset lungs. (A) 2-dimensional hierarchal clustering of DE transcripts
from infected lungs. The heatmap shows log2 expression of transcripts with greater than 2-fold change relative to uninfected marmoset lung among
all the MERS-CoV-infected samples. The row dendrogram shows clusters of gene expression and the column dendrogram shows clusters of samples
with similar transcriptional profiles. (B) Functional network of genes demonstrating the functional relationship between inflammatory mediators and
connective tissue adhesions. (C) Molecule activity prediction (MAP) network of cytokines, chemokines, growth factors, and receptors at 4 dpi. Red
molecules are those upregulated in the data set, teal molecules are those downregulated in the dataset, orange molecules are those predicted to be
activated, and dark blue molecules are those predicted to be inhibited. Orange lines indicate a predicted activation effect, blue lines indicate a
predicted inhibitory effect, and gray lines indicate a relationship without a known or predicted activity or inhibition.
doi:10.1371/journal.ppat.1004250.g007
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clinical trials in humans. As such, this new MERS-CoV disease
model is a significant contribution to reducing the impact of
MERS-CoV on global public health.
Materials and Methods
Ethics statement
All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Rocky
Mountain Laboratories (RML), and performed following the
guidelines of the Association for Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC) by certified
staff in an AAALAC-approved facility, following the guidelines
and basic principles in the United States Public Health Service
Policy on Humane Care and Use of Laboratory Animals and the
Guide for the Care and Use of Laboratory Animals. All
procedures were carried out under a combination of Ketamine
and isoflurane anesthesia by trained personnel under the
supervision of veterinary staff and all efforts were made to provide
for the welfare and to minimize any suffering in accordance with
the ‘‘Weatherall report for the use of non-human primates’’.
Animals were housed in adjoining individual primate cages
allowing social interactions, under controlled conditions of
humidity, temperature and light (12-hour light/12-hour dark
cycles). Food and water were available ad libitum. Animals were
monitored twice daily (pre- and post-challenge) and fed a
combination of commercial New World monkey chow, rice cereal
supplemented with calcium, ZuPreem marmoset, wax worms/
larvae and fruit twice daily by trained personnel. Endpoint criteria,
as specified by the RML IACUC approved score parameters, were
used to determine when animals should be humanely euthanized.
Animals were euthanized by exsanguination under deep isoflurane
anesthesia. The work with infectious HCoV-EMC/2012 was
approved under BSL3 conditions by the Institutional Biosafety
Committee (IBC). Sample inactivation was performed according
to standard operating procedures approved by the IBC for
removal of specimens from high containment.
Study design
In order to establish a more severe animal model for MERS-
CoV, the interaction of the common marmoset DPP4 with the
MERS-CoV spike protein was modeled. Subsequently, experi-
mental inoculation of common marmosets was performed to
determine whether they would serve as an improved disease
model. Nine male common marmosets (Callithrix jacchus; 2–6
years old) were randomly assigned a number (CM1–CM9) and
subsequently inoculated with MERS-CoV (strain HCoV-EMC/
2012) intranasally with 100 ml in each nare, 500 ml orally, 500 ml
intratracheally and 50 ml in each eye with DMEM containing
46106 TCID50/ml (total dose 5.2610
6 TCID50). Necropsies of
three animals were scheduled on 3 dpi (CM1–CM3) and 6 dpi
(CM4-6). The three remaining animals (CM7–CM9) were not
scheduled for euthanasia, but were used to study survival and
seroconversion upon inoculation of animals with MERS-CoV
(Fig. 2A). The animals were observed twice daily for clinical signs
of disease and scored using a clinical scoring system prepared for
common marmosets (Table S2). The in-study euthanasia criteria
were established prior to the start of the experiment based on the
scoring sheet and euthanasia was indicated at a clinical score of 35
or above (Table S2). During the course of the study, animals CM5
and CM9 were euthanized on 4 dpi as they reached euthanasia
criteria. On 1, 3, 6, 9, 13 and 20 days post inoculation, clinical
exams were performed on anaesthetized animals, x-rays were
taken and nasal and oral swabs were collected in 1 ml DMEM
with 50 U/ml penicillin and 50 mg/ml streptomycin. Tempera-
ture was monitored with IPTT-300 temperature probes (BMDS)
that were injected interscapularly prior to the start of the
experiment. Blood was collected prior to the start of the study
and at euthanasia for hematology and blood chemistry analysis.
The total white blood cell count, lymphocyte, platelet, reticulocyte,
and red blood cell counts, hemoglobin, hematocrit values, mean
cell volume, mean corpuscular volume, and mean corpuscular
hemoglobin concentrations were determined from EDTA blood
with the HemaVet 950FS+ laser-based hematology analyzer
(Drew Scientific). Samples of the following tissues were collected:
conjunctiva, nasal mucosa, tonsil, mandibular lymph node,
salivary gland, trachea, all four lung lobes, mediastinal lymph
node, inguinal lymph node, axillary lymph node, mesenteric
lymph node heart, liver, spleen, kidney, adrenal gland, pancreas,
ileum, colon transversum, urinary bladder, testes, frontal brain,
cerebellum and brain stem.
Amino acid and binding energy comparison between
human and marmoset DPP4
Amino acid sequence alignment was generated using the
human, ferret and marmoset DPP4s (accession numbers
NP_001926.2, DQ266376 and XM_002749392 respectively)
using CLUSTALW2 [35]. The human DPP4 structure model
(PDB ID: 4KR0, Chain A) was used as template to highlight the
location of the amino acid differences between the human and
marmoset DPP4s.The initial model was built using Nest [36]
based on the amino acid alignment and the human DPP4
structure. The resulting structural model was briefly optimized
using the TINKER minimization program ‘‘minimize.x’’ with
OPLS all-atom force field and L-BFGS quasi-Newton optimiza-
tion algorithm [37]. For the marmoset and ferret DPP4, the RBD/
DPP4 complex model was generated by merging the RBD domain
(PDB ID: 4KR0, Chain B) with the DPP4 model, which was then
subjected to the binding energy calculation using an all-atom
distance-dependent pairwise statistical potential, DFIRE [38]. The
energy difference between the complex and two individual
structures - DPP4 and RBD - was taken as the binding energy.
Virus and cells
HCoV-EMC/2012 [21] was kindly provided by the Depart-
ment of Viroscience, Erasmus Medical Center, Rotterdam, The
Netherlands and propagated once in VeroE6 cells in DMEM
(Sigma) supplemented with 2% fetal calf serum (Logan), 1 mM L-
glutamine (Lonza), 50 U/ml penicillin and 50 mg/ml streptomycin
(Gibco) (virus isolation medium). VeroE6 and LLC-MK2 cells
were maintained in DMEM supplemented with 10% fetal calf
serum, 1 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml
streptomycin.
Histopathology and immunohistochemistry
Histopathology and immunohistochemistry were performed on
marmoset tissues. After fixation for 7 days in 10% neutral-buffered
formalin and embedding in paraffin, tissue sections were stained
with hematoxylin and eosin (HE). To detect HCoV-EMC/2012
antigen, immunohistochemistry was performed using a rabbit
polyclonal antiserum against HCoV-EMC/2012 (1:1000) as a
primary antibody for detection of HCoV-EMC/2012 antigen.
Immunohistochemistry for DPP4 (CD26) was performed with a
rabbit polyclonal antiserum (1:400) (Abcam). To confirm the cell
type of infected cells a subset of specimens were stained with an
antibody against cytokeratin (1:100) (Dako) and the rabbit
polyclonal against HCoV-EMC/2012. Fluorescently labeled goat
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anti-mouse (AlexaFluor 488) goat anti-rabbit (AlexaFluor 594)
were used for detection. Tissues from an uninfected control animal
was obtained from Primate Biologicals and used to validate all in
situ and immunohistochemistry procedures.
RNA extraction
RNA was extracted from swab and whole blood samples using
the QiaAmp Viral RNA kit (Qiagen) according to the manufac-
turer’s instructions. Tissues (30 mg) were homogenized in RLT
buffer and RNA was extracted using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. For whole tran-
scriptome sequencing, tissues collected from the right lower lobe of
the lung were homogenized in TRIzol reagent and frozen at 2
80uC. The TRIzol was phase separated and total RNA was further
purified from the aqueous phase using the miRNeasy kit (Qiagen)
according to the manufacturer’s instructions.
Virus isolation
Weighed tissue samples were homogenized in a TissueLyzer II
(Qiagen) after addition of 1 ml DMEM. Homogenates were
centrifuged to pellet cellular debris and 10-fold dilutions of
homogenate were made and subsequently inoculated onto VeroE6
and LLC-MK2 cells for virus isolation. After 1 hr, cells were
washed once with DMEM and supplemented with virus isolation
medium. Cells were scored for cytopathic effect 5 days following
infection.
Quantitative PCR
For detection of viral RNA, 5 ml RNA was used in a one-step
real-time RT-PCR upE assay [39] using the Rotor-Gene probe kit
(Qiagen) according to instructions of the manufacturer. In each
run, standard dilutions of a titered virus stock were run in parallel,
to calculate TCID50 equivalents in the samples.
Total RNA library preparation
Total RNA libraries were constructed using the Illumina
TruSeq Stranded Total RNA Preparation Kit (Illumina) accord-
ing to the manufacturer’s guide. Input RNA was rRNA reduced
using the Ribo-Zero Magnetic Kit (Human/Mouse/Rat), (Epi-
centre), and rRNA reduction was verified by BioAnalyzer 2100
(Agilent Technologies). Libraries were quality controlled and
quantitated using the BioAnalzyer 2100 system and mass
measurement using QuBit (Life Technologies). The libraries were
clonally amplified on a cluster generation station using Illumina
version 2 MiSeq reagents to achieve a target density of
approximately 1000 K–1200 K clusters/mm2 on the flow cell.
The resulting libraries were then sequenced on an Illumina MiSeq
system at single reads of 50 bp, and were processed on the system
to generate quality control metrics and FASTQ files with MiSeq
Reporter 2.3.32.
Next generation sequencing
Raw reads were trimmed to 50 base pairs (bp) and adapter
sequences were removed. We mapped the 50 bp reads to a
custom-compiled set of known ribosomal sequences (human,
mouse) using the short-read aligner software Bowtie v. 1.0.0 [40]
to remove potential rRNA sequences. The remaining unmapped
reads corresponding to MERS-CoV genome (GenBank accession
no. JX869059.2) were also removed using Bowtie. All the
remaining reads were mapped to the common marmoset
(Callithrix jacchus) genome assembly (Genome assembly: C_jac-
chus3.2.1, GCA_000004665.1) downloaded from Ensembl (ver-
sion 74) using STAR v.2.3.0.1 [41]. Gene level quantification was
obtained using HT-seq (http://www-huber.embl.de/users/
anders/HTSeq/doc/overview.html) with Ensembl annotation
(v74). For the downstream analyses we only retained those
transcripts with at least 40 raw read counts in at least one sample.
The raw read counts were normalized using edgeR [42]. For the
calculation of expression ratios, an offset of 5 was added to the
normalized expression levels, i.e. counts per million (cpm) values to
dump down variations due to low abundances. We identified
transcripts with greater than 2-fold change relative to the
uninfected control, and used Spotfire DecisionSite (Tibco) to
perform hierarchical clustering using the unweighted pair group
method with arithmetic means (UPGMA) method, and generate
heatmaps. Functional enrichment analysis was performed using
Ingenuity Pathway Analysis (IPA). Raw data were deposited into
the Sequence Read Archive (SRA) via the Gene Expression
Omnibus (accession number pending).
Data and materials availability
GEO Accession #GSE55023.
Supporting Information
Figure S1 Temperature, hematology and clinical blood chem-
istry from common marmosets inoculated with MERS-CoV. (A)
Temperature was monitored via injectable temperature probes.
Hematology values for (B) white blood cell, (C) neutrophils and
(D) red blood cells were determined on a HemaVet. Clinical blood
chemistry values for the liver function (E) aspartate aminotrans-
ferase (AST), (F) alanine aminotransferase (ALT), (G) alkaline
phosphatase (ALP), (H) bilirubin; kidney function (I) blood urea
nitrogen (BUN), (J) creatinine; and (K) total protein and (L)
albumin were determined.
(TIF)
Figure S2 Gross lung parameters at necropsy from common
marmosets inoculated with MERS-CoV. (A) Gross pathology
scores representing the area of lesion on dorsal and ventral surface
of the upper and lower lung lobes. Shaded area represents the
range of values, solid line indicates the median value, error bar
represents the 95% confidence interval. P values from 2-way
ANOVA are indicated above the graph. (B) Lung weight to body
weight ratio.
(TIF)
Table S1 Clinical observations in common marmosets inocu-
lated with MERS-CoV between 1 and 6 dpi. Animals were
observed twice daily and clinical parameters were recorded.
(DOCX)
Table S2 Clinical score sheet for common marmosets inoculated
with MERS-CoV.
(DOCX)
Table S3 Summary of radiographic changes of common
marmosets inoculated with MERS-CoV. The quality and location
of interstitial infiltration observed from ventral-dorsal and lateral
x-rays is indicated.
(DOCX)
Table S4 Histopathology score in MERS-CoV inoculated
common marmosets based on area of tissues affected by
microscopic lesions.
(DOCX)
Table S5 Virus isolation from tissues of common marmosets
inoculated with MERS-CoV in VeroE6 or LLC-MK2 cells.
(DOCX)
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Table S6 Differentially expressed genes identified to be involved
in fibrosis pathways.
(DOCX)
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